Acute myeloid leukemia (AML) is a biologically and clinically heterogenous disease.
Although similar chemotherapeutic regimens were used for the majority of patients with AML …

Abstract 2725 Already for decades, controversy exists as to whether CD34 expression
predicts for poor prognosis (Kanda et al, Cancer 88: 2529, 2000). One of the complicating …

Background The stem cell marker CD34 is expressed by leukemia blasts only for a subset of
patients with acute myelogenous leukemia (AML). It is still controversial as to whether CD34 …

BACKGROUND AND OBJECTIVES: The various epitopes of the CD34 molecule have been
classified according to their different sensitivities to enzymatic cleavage by neuraminidase …

Aberrant antigen expression in acute myeloid leukemia (AML) has been extensively studied
in the West with limited reports from Taiwan. We carried out this retrospective study to …

Current views about the origin of acute lymphoid leukemia (ALL) emphasize the importance
of maturation arrest at a precursor cell level. Recently, the CD22 antigen has been identified …

The prognostic significance of immunophenotypical properties of leukaemic cells is well
known. However, the biological and clinical significance of CD7 and CD56 antigen …

Human AC133 antigen is a 5-transmembrane molecule that belongs to the prominin family.
1-4 In the hematopoietic system, AC133 expression is restricted to a subset of CD34+ …

In the absence of truly leukemia-specific antigen, antigen combinations were identified in
leukemia cells that are absent or extremely rare among normal hemopoietic cells. Some of …

From a cohort of 220 adults with newly diagnosed acute myeloid leukemia (AML), 8 (3.6%)
exhibited a rare variant of aberrant membrane phenotype. It was characterized with typical …